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Abstract 
Organometallic compounds currently occupy an important place in the field of medicinal 
inorganic chemistry due to the unique chemical properties of metal coordination compounds. 
Particularly, metal compounds ligated by N-heterocyclic carbenes (NHC) have shown high 
potential for biomedical applications as antimicrobial and anticancer agents during the recent 
15 years. Although further studies are necessary to validate the modes of action of this family 
of compounds, a number of biological targets have been identified, including DNA secondary 
structures.  
This perspective review aims at providing an overview of the most representative examples of 
metal NHC complexes reacting with nucleic acids via different binding modes. It is organized 
according to the type of DNA secondary structure targeted by metal NHCs, highlighting the 
possible advantages of biomedical applications, including therapy and imaging. 
 
 
 
 
1. Introduction 
Since its regulatory approval for testicular and ovarian cancers in the USA in 1978, cisplatin 
developed into an indispensable and effective anticancer agent.1 Its cytotoxic properties stem 
from direct DNA binding which induces a series of signal transduction-pathways of which some 
lead to cell death.2,3,4 However, early observations of acquired drug-resistance and severe side 
3 
 
effects triggered the development of further derivatives of this compound’s class that 
culminated in the approval of carboplatin and oxaliplatin.5,6 The pharmacological activity of 
platinum agents was found to be affected by the ligands coordinated at the metal center and this 
insight was exploited as a basis for the rational design of next-generation anticancer agents. 
In this context, organometallic compounds are promising candidates for future therapeutic 
schemes. By definition, organometallic complexes are characterized by at least one metal–
carbon bond. Given that a carbon atom offers four bonding orbitals and three hybridization 
types, organometallic complexes yield an abundant number of stereochemically and 
geometrically diverse scaffolds that allow fine-tuning of their biological and physiochemical 
properties. Moreover, the metal–carbon bonds are kinetically inert and display high stability, 
essential to control metallodrugs speciation in aqueous environment. Organometallic 
complexes are well-established in homogenous catalysis. In particular, they are widely applied 
in the activation of small molecules, olefin polymerization and in different organic 
transformations such as carbonylation reactions and carbon-carbon bond formations.7 Beyond 
that, organometallic scaffolds attract increasing interest in drug discovery because they offer a 
large unexplored chemical area with respect to biological and medicinal applications.8 Typical 
representatives of ligands used for metal-carbon complexation include carbonyls, alkynyls, 
cyclopentadienyls, arenes, cyclometalated and N-heterocyclic carbenes (NHCs) as illustrated 
in Fig. 1.9 As an example, Ferroquine is a ferrocene-containing antimalarial agent that currently 
undergoes phase II clinical trials and shows promise to overcome chloroquine resistance.10 A 
cytostatic cobalt(0) complex (Co-AcS, AcS = acetylsalicylic acid) containing carbonyls and an 
alkyne as ligands has been shown to inhibit COX-2 via different binding modes than AcS alone, 
and the ruthenium(II) complex [Ru(η6-arene)(PTA)Cl2] (RAPTA-C; PTA = 1,3,5-triaza-7-
phosphaadamantane) displayed strong antimetastatic activity in ovarian and colorectal 
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xenografts.11,12 Consequently, it is now generally accepted that even simple modifications of 
organometallic scaffolds dictate target preferences. 
 
Fig. 1 - Structures of organometallic compounds used for medicinal purposes. 
 
Within this framework, N-heterocyclic carbenes (NHCs) are of particular interest among the 
ligand scaffolds available for novel bioactive organometallic complexes. They consist of a 
neutral heterocycle with a two-electron donating carbenic carbon between two nitrogen atoms. 
Usually, NHCs are singlet carbenes conferring strong σ-donor properties as a ligand and low 
tendency to dimerize. The synthesis of the first NHC metal complex dates back to 1968, and 
since the first reports on free stable NHCs and their applicability as ligands in the early 
1990ies13 NHC popularity increased strongly, while even gradually supplanting the use of 
conventional tertiary phosphines as σ-donors. Notably, NHC carbenes form strong bonds with 
metals yielding organometallic complexes of high chemical and thermal stability, and they are 
also easily derivatised and even immobilized on carrier materials.14 
Recent developments in inorganic drug discovery of metal NHCs, focus on coinage (Au, Ag, 
Cu) and platinum-group metals (Pt, Ru, Pd, Os, Ir) and their structure-activity relationships as 
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well as biological targets are being elucidated.15–19,20 The biological modes of action of 
antiproliferative NHC complexes have been investigated for several of these metal ions and led 
to the identification of different potential molecular targets.12,15–17,19–23 Among these 
mechanisms, cell cycle arrest and mitochondrial dysfunctions (e.g. ROS production, changes 
in mitochondrial membrane potential, cytochrome c release and caspase activation) may be 
responsible for triggering apoptosis in cancer cells and this is on the one hand caused by the 
interaction of such metal-based drug candidates with proteins.24,25 For example, selected gold(I) 
NHC complexes are assumed to induce apoptosis by inhibition of thioredoxin reductase 
(TrxR).26 The latter is a seleno-enzyme that is overexpressed in several cancer cells and plays 
an important regulatory role in the cellular redox-balance.21,26 Other enzymatic targets of 
anticancer metal NHC-based complexes are glutathione reductase (GR), deubiquitinase (DUB), 
cyclooxygenase (COX) and cathepsin B, respectively.24 Readers are directed to further 
references to cover the implication and modes of actions of metal NHCs as antimicrobial 
drugs.23 
Interestingly, the cyclophane NHC-based Au(I) complex comprising an ortho-substituted 
xylylene scaffold (Figure 1) in addition to be a cytotoxic agent, is luminescent, most likely as 
a result of short Au(I)…Au(I) contacts (< 3 Å) induced by the cyclophane ligand framework.27 
This distance can be modulated as a function of the bridging unit within the bis-NHC ligand. 
Luminescence properties of metal complexes are particularly attractive for monitoring their 
intracellular distribution, e.g. for targeting specific cells/organs. As an example, Ag(I) and 
Au(I) NHC complexes bearing a fluorescent anthracenyl ligand were examined for cytotoxicity 
in normal and tumor cells.28 Fluorescence microscopy experiments showed that both 
compounds enter cells, and are particularly efficient in penetrating tumor cells where they reach 
the nuclear compartment. 
More recently, acridine wingtip NHC-based Au(I) complexes showed strong antiproliferative 
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activity and fluorescence based on IL transitions, and were found to be localized primarily in 
lysosomes of A549 cells by fluorescence microscopy, and in the nuclei to a lower extent.29 
From recent studies, it emerged that NHC-derived organometallic anticancer agents show the 
potential to target specific DNA secondary structures and often in a purely non-covalent mode 
of binding. Selectivity for such DNA secondary structures is expected to increase target 
selectivity, while reducing off-target activity and, therefore, reducing side effects. In this 
perspective, we aim at categorizing DNA secondary structures as targets for organometallic 
NHC complexes as anticancer agents, and at highlighting the promising therapeutic gains from 
altering such structures. Similarly, fluorescent metal NHC probes targeting DNA secondary 
structures might be useful for imaging purposes to uncover their implications of in tumor 
biology. Thus, the different modes of binding will be discussed in the following chapters, as 
well as possible future developments in the field.  
 
2. Metal NHC Complexes Targeting DNA Secondary Structures 
DNA is a peculiar molecule of high complexity that carries the genomic code. Two 
complementary strands are associated in a helix that is condensed into chromosomes by 
wrapping the double helix around histone octamers as nucleosome core particles (Figure 2). 
However, loosening this tightly packed arrangement is required for transcription. The 
corresponding euchromatin can be further unfolded and forms specific structural motifs of DNA 
architecture. Duplex DNA, mismatched DNA and replication forks represent double-stranded 
motifs, while promotor G-quadruplexes (G4s), telomeric G4s and i-motifs represent intrastrand 
structures (Figure 2). 
From a therapeutic perspective, DNA plays a prevalent role in the majority of cytotoxic 
therapies. For essential in vitro experiments DNA is easily available from natural sources 
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(predominantly calf thymus (CT)-derived). Today, it is possible to readily detect interactions of 
DNA with potential drugs by a variety of conclusive analytic and spectroscopic methods, 
involving gel electrophoresis, circular dichroism, spectroscopy, turbidimetry, DNA melting 
experiments as well as nuclear magnetic resonance (NMR), X-ray diffraction and mass 
spectrometry.3,4,30,31 Figure 3 depicts the adducts of different DNA secondary structures with 
metallodrugs featuring different binding modes including (A) coordination, (B) insertion and 
(C) stacking, which will be discussed in this review in more detail. 
Direct coordinative binding to the DNA double strand was the initial target engagement of 
inorganic anticancer agents, especially platinum agents. Similarly, the use of coordination-
based compounds to recognize DNA in a supramolecular fashion is undisputed.32 However, it 
has only more recently emerged that DNA is a structurally heterogeneous molecule that can 
adopt defined secondary structures, which in turn may be targeted by small molecules. Here, 
the aim is to provide a rationale for selectively targeting secondary DNA structures and to show 
that organometallic NHC complexes are especially suited as scaffolds for targeting these 
structures.  
 
 
Fig. 2 - Scheme of the DNA secondary structures that may be targeted by organometallic NHC 
complexes. 
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Fig. 3 - The binding modes of metal-based anticancer agents to specific DNA secondary 
structures are exemplified by X-ray crystal structures: (A) Activated cisplatin binding to N7 of 
neighbouring guanines in duplex DNA (B) Insertion of Δ-[RuII(2,2’-
bipyridine)2(dipyridophenazine)]
2+ into DNA mismatches A:A site (zoom) and abasic sites and 
(C) Binding of [AuI(9-methylcaffein-8-ylidene)2]
+ to a telomeric G-quadruplex via non-
covalent interactions. The pdb accession codes are given and the structures were generated 
using NGL. 
 
2.1 Targeting Duplex DNA 
The double-helical architecture of DNA (duplex DNA) was one of the first therapeutic targets 
for cytotoxic anticancer drugs.33 Basically, there are three biologically active double helical 
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DNA structures. A- and B-DNA are made up of a right-handed helix with B-DNA being the 
predominate form. In contrast, Z-DNA is a left-handed helical form. The binding of metal-
based drugs to DNA was mainly investigated on right-handed duplex DNA, while a few studies 
exist on their interaction with left-handed duplex DNA.34 Interestingly, the reactivity of metal-
based anticancer agents towards duplex DNA can be tuned to yield compounds that coordinate 
directly to nucleobases or intercalate/ between base pairs of duplex DNA.32 Additionally, metal-
based drug candidates can be designed to damage DNA structures by hydrolytic and/or 
oxidative processes. This often results in conformational changes of DNA, which disrupts 
transcription or DNA synthesis. Interestingly, organometallic NHC compounds based on 
different metal centers showed promising results in recent years as potential duplex DNA 
targeting anticancer agents via different binding modes, and representative examples are given 
below.  
2.1.1 DNA cleavage  
Double-strand cleavage of DNA is ubiquitous and essential for the maintenance of cellular 
functions. This process is catalysed by topoisomerases and restriction enzymes, which are 
nucleases and responsible for the regulation of DNA supercoiling and for defence mechanisms, 
respectively.35 Interestingly, artificial nucleases were designed to interfere with DNA helicity 
for therapeutic purposes.36 Nucleases cleave DNA by hydrolysis of the phosphodiester 
backbone of DNA. Similarly, metal-based therapeutics can undergo ligand substitution 
reactions with water molecules able to generate hydroxyl nucleophiles,31,36,37 which in turn 
induce the nucleophilic attack on the phosphate backbone of DNA.38 The resulting cleavage 
generates 5’-OPO3 and 3’-OH fragments, which are similar to those obtained from naturally 
occurring nucleases (Scheme 1A).37,39 
Moreover, certain metal complexes react with oxygen or hydrogen peroxide to form reactive 
oxygen species (ROS) and damage DNA in an oxidative manner36,37 generating Fenton-type 
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reactions.40 Highly reactive hydroxyl radicals (·OH) formed in the presence of Fe(II), for 
example, can add to double bonds of DNA bases or abstract hydrogen atoms from the methyl 
group of thymine and the ribose building block, respectively.41 Scheme 1B illustrates DNA 
cleavage after H-abstraction at the sugar moiety. 
 
 
Scheme 1 - Postulated mechanisms of (A) hydrolytic cleavage of DNA and (B) oxidative 
cleavage at ribose moiety.37 
 
Figure 4 shows representative cytotoxic metal NHC complexes studied for their potential 
activities as chemical nucleases. As a first example, Srivastava and coworkers investigated the 
DNA binding properties of luminescent bis-NHC complexes based on Au(I) ions (1).42 Upon 
treatment with the gold compounds, the DNA extracted from U373-GB glioblastoma cells was 
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highly fragmented as monitored by gel electrophoresis assays. This effect was attributed to an 
elevated DNA binding affinity of the benzyl-functionalization of the carbene ligands.  
A Ru(II) NHC complex (2) demonstrated a strong antiproliferative effect towards human colon 
carcinoma (HCT-15) and epidermoid cancer (Hep2) cells.43 In gel electrophoresis assays, 
distinct dose-dependent DNA interactions were observed, which induced DNA cleavage, as 
well as DNA aggregation upon increasing the metal concentration up to 100 µM. It was 
suggested that 2 would intercalate into DNA and subsequently catalyze DNA cleavage. 
McAlpine and coworkers showed that the incorporation of an imidazole-type NHC ligand to a 
rhodium(I) cyclooctadiene (COD) fragment (3) generated a chemical nuclease with remarkable 
antiproliferative activity against HCT116 colon cancer cells (IC50: 3 µM).
44 Mechanistic 
investigations underlined DNA interactions to be causative for the antiproliferative effect. Gel 
electrophoresis assays revealed that this compound is capable of binding to supercoiled plasmid 
DNA and trigger a transformation to the nicked form. Furthermore, the restriction endonuclease 
BamHI was not able to digest the DNA when incubated with 3, indicating a conformational 
change of the DNA upon interaction with the metallo-NHC compound. In fact, the 
conformational change induced by this organo-rhodium(I) compound was suggested to lead to 
DNA replication arrests as observed in BrdU incorporation assays with HCT116 cells, which 
also impaired cellular migration. 
Due to their redox properties, copper compounds are well-known for their DNA cleaving 
activities, in particular by inducing oxidative damage.45 Consequently, copper(I) NHC 
complexes bearing either one (4, Figure 4) or two 1,3-bis(2,4,6-trimethylphenyl)imidzolin-2-
ylidene carbene ligand moieties were investigated for their interaction with duplex DNA.46 In 
comparison to cisplatin, the neutral compound 4 demonstrated enhanced antiproliferative 
activity in several cancer cell lines. For example, the copper(I) complex exhibited an IC50 value 
of 0.075 µM in MCF-7 breast adenocarcinoma, while cisplatin has an IC50 of only ca. 10 µM 
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against the same cell line. Similarly, 4 was 150-fold more effective against HL60 promyelocytic 
leukemia cells compared to the platinum(II) compound. Notably, chemical nuclease activity 
was only demonstrated for the mono(NHC) copper(I) complex, whereas no DNA interaction is 
observed for the respective bis-NHC compound. Gel mobility assays demonstrated single 
strand cleavage of supercoiled plasmid DNA by 4 to the nicked form under aerobic conditions. 
Interestingly, the same experiment conducted in the presence of a singlet oxygen (NaN3) or 
hydroxyl radical (DMSO) scavenger quenched this behavior. Therefore, it was concluded that 
4 was DNA damaging by generating ROS only under normoxic conditions.  
 
Fig. 4 - Antiproliferative metal NHC complexes studied for their potential activities as chemical 
nucleases. 
 
2.1.2 Direct coordination 
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Alkylating agents bind irreversibly to DNA and induce conformational changes such as bending 
or unwinding, thus hampering vital replication and transcription processes.3,47 The earliest 
examples of direct interactions between metallodrugs and DNA stem from platinum(II) 
anticancer compounds that coordinatively bind to DNA upon ligand exchange as revealed by 
X-ray crystallography (Figure 3A).48 For example, activated cisplatin coordinates favourably 
to the nucleophilic N7 position of purine bases, especially guanine. Monometallic intrastrand, 
and to a lesser extent interstrand crosslinks, can form upon hydrolysis of both metal–halido 
bonds.3,6,49  
Concerning the case of experimental gold-based anticancer compounds, their mode of action is 
governed by the inhibition of key proteins/enzymes and/or possible oxidative damage, leading 
to cell death;21,48 while direct coordination of gold compounds to duplex DNA has been  thought 
to be of scarce relevance. Especially those compounds bearing at least one labile ligand have 
been shown to be susceptible to interact with cellular nucleophiles on biomolecules, including 
cysteine-containing proteins (e.g. albumin or metallothionein) and thiol/selenol-based enzymes 
(e.g. TrxR).  
Nevertheless, Gust and coworkers demonstrated that gold(I) NHC complexes 5a and 5b (Figure 
5) – with ligands derived from pharmacologically active 4,5-diarylimidazole bearing -OCH3 
and -F substitutions – present important cytotoxic properties and moderate coordinative binding 
to duplex DNA.50 In fact, measurements of the binding efficiency of the complexes to salmon 
testes DNA showed increased binding for 5a and 5b (2.03 pmol/µg and 1.03 pmol/µg, 
respectively) compared to Et3PAuCl (0.11 pmol/µg), but which was still weaker than cisplatin 
(14.2 pmol/µg). Due to discrepancies between DNA binding studies and the respective 
antiproliferative activities of the complexes, the authors suggested additional mechanisms to be 
responsible for the biological activity. 
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Mono- and homobimetallic transplatin-type cytotoxic agents incorporating a NHC-ligand (6a-
b, Figure 5) were also reported to inhibit the growth of a panel of cancer cell lines more 
efficiently than cisplatin.51 This effect correlated with the strong nuclear accumulation of 6a-b 
in A2780 and A2780-DDP cell lines, but not with the platination of DNA. For example, 
compound 6a exhibited a 16-fold higher nuclear accumulation than cisplatin, but DNA 
platination was only enhanced 1.3-fold in A2780 cells as revealed by analyzing the treated cells 
with inductively coupled plasma mass spectrometry (ICP-MS). Interestingly, gel 
electrophoresis assays with duplex DNA, containing sequences of TGGT, TGTGT and 
GTTTG, respectively, demonstrated that metal-DNA adduct formation occurred and involved 
specific direct coordination to guanine bases.  
Furthermore, novel mechanistic behaviors were reported for a polymeric formulation of 
platinum(II) NHC fragments attached to a bidentate polyethylenimine ligand, a known 
transfection agent (7, Figure 5).52 Notably, the complex is much more effective than cisplatin 
and oxaliplatin against HCT-116 (human colorectal adenocarcinoma) cells. Evaluation of the 
subcellular distribution of 7 demonstrated that only 16% of the total intracellular platinum 
accumulated in the nucleus while 20% was found in mitochondria. Comparatively, 57% of 
oxaliplatin located in the nucleus whereas only 3.5% were found in mitochondria. The dual 
targeting of nuclei and mitochondria by 7 has been hypothesized to contribute to the promising 
anticancer effects in cell that exhibit resistance towards common platinum drugs. Moreover, in 
vivo experiments confirmed that 7 is more effective than oxaliplatin in reducing tumor growth.53 
In fact, an almost two-fold higher tumor volume inhibition (80%) with respect to oxaliplatin 
was reached in a xenograft mouse models bearing HCT-116 tumor, upon treatment with 10 
mg/kg of 7 once every 48 h. Notably, no side effects were observed with compound 7 whereas 
the treatment of oxaliplatin induced hemorrhagic events.  
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Recently, Schobert and coworkers performed extensive investigations on the effect of cis- and 
trans-configured platinum(II) NHC complexes on biological activities including DNA 
interactions.53,54  In vitro screening of a series of 1,3-dibenzylimidazolylidene Pt(II) complexes 
with different leaving groups trans to it (8a-c, Figure 5) showed that the antiproliferative 
activity strongly depends on the nature and position of this ligand (PPh3, 2-picoline, Cl and 
NHC, respectively).53 All complexes were effective by inhibiting the growth of different cancer 
cells (e.g. Panc-1, MCF-7/Topo and HCT-116) and of the cisplatin-resistant colon cancer cell 
line HT-29. Especially, the cationic compound 8c exhibited IC50 values in the nanomolar range. 
Notably, the cytotoxicity followed the intuitive trend 8a < 8b < 8c, according to lipophilic 
character. Mechanistic investigations showed that the interactions with the DNA were 
dependent on (i) the presence of a leaving group trans to the NHC, and (ii) a low bulkiness of 
the ligands in cis-position to the NHC. A different binding mode compared to cisplatin was 
suggested based on the minor effect of 8a-c on the gel mobility of the relaxed DNA form. 
Interestingly, it was demonstrated that the higher the number of PPh3, which might sterically 
restrict the contact with DNA or the hydrolysis of the leaving chloride, ligands, the lower the 
ability and rate to irreversibly bind to double-stranded CT DNA.  Finally, the authors suggested 
that the trend of cell growth inhibition in this series was a result of the ability of the compounds 
to cause DNA aggregation. For example, the bis-carbene 8d did not cause aggregation using 
light scattering experiments, while the mono-carbene 8c induced the condensation of 50% of 
the total amount of DNA at a concentration of 0.51 μM.54 These results, together with those of 
the EMSA and EtdBr studies, support the hypothesis that 8c might interact with DNA 
predominantly via noncovalent interactions, facilitated by its positive charge. 
Thereupon, cis-oriented bis-NHC platinum(II) complexes (9a-b, Figure 5) were analyzed for 
their anticancer activities towards different cell lines.54 Overall, both complexes showed 
remarkable antiproliferative activity but the “delocalized lipophilic cationic” (DLC) 9b was 
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about 10-fold more potent compared to 9a with IC50 values in the nanomolar range. 
Electrophoretic mobility shift assays with plasmid DNA demonstrated a similar behavior of the 
neutral 9a compared to cisplatin as both compounds were able to unwind the plasmid DNA in 
a concentration-dependent manner. Both 9a-b induced DNA aggregation, with 9b being the 
most efficient. Interestingly, analogous trans-bis(NHC) Pt(II) complexes did not present the 
same behavior. 
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Fig. 5 - Metal NHC complexes with potential coordinative binding modes to duplex DNA. 
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A family of half-sandwich ruthenium(II)(arene) compounds featuring NHC ligands (e.g. 
exemplified by 10, Figure 5) showed weak antiproliferative effects against cancer cells and 
ruthenation of salmon testes DNA of 15–50%, which was lower compared to cisplatin.55 Later 
on, the same authors then showed the covalent binding potential of a rhodium(I) COD complex 
(11) with a similar ligand to duplex DNA.56 In contrast to the half-sandwich ruthenium NHCs, 
11 showed potent antiproliferative activity against MCF-7 human breast adenocarcinoma (IC50 
ca. 0.6 µM) and cisplatin-resistant HT-29 colon carcinoma (IC50 ca. 0.9 µM) cell lines. 
Moreover, treatment of salmon testes DNA with 11 showed that 72% of the rhodium was bound 
to DNA after 4 h incubation. However, the compound metallated albumin to a similar extent 
(67% after 2 h). Further investigations demonstrated the potential to induce apoptosis-inducing 
changes of mitochondrial membrane potential in Nalm-6 leukemia cells. 
 
2.1.3 Intercalation 
Intercalation denotes the non-covalent stacking interaction of planar (heterocyclic) aromatic 
moieties with adjacent base pairs in duplex DNA. As a result, the double helix structure is 
affected and undergoes conformational changes involving lengthening, stiffening, and 
unwinding, respectively, which cause similar therapeutic effects compared to covalent DNA 
binding, i.e. inhibiting replication and transcription.37 Intercalating agents such as doxorubicin 
and anthracyclines in general remain important and widely applied anticancer therapeutics.32 
Moreover, chloroquine completed phase III clinical trials for the treatment of glioblastoma 
multiform and underlines current clinical developments in this field.57 Apart from organic small 
molecules, intercalating agents of various metals have been reported over the last years (e.g. 
Zn, Pt, Rh or Ru).58 Typical metallointercalators contain cyclometalated and N-donor ligated 
aromatic ring systems, e.g. HCNN (6-phenyl-2,2’-bipyridine), phenanthroline or terpyridine, 
and exhibit favourably square-planar or octahedral geometries.59  
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Despite a structure that is atypical for metallointercalators, Castro and coworkers demonstrated 
the possibility of non-covalent DNA binding mode for the dinuclear silver mono-N-
heterocyclic carbene complex 12 (Figure 6).60 The complexes displayed antiproliferative 
activity against six tumor cell lines of different origin, at concentrations below 30 µM. Their 
interaction with CT DNA was investigated using different methods including absorption 
spectral titration. Thus, an increase of CT DNA amounts relative to the test compound resulted 
in a decrease in absorption of 20% with a slight red shift (~ 7 nm), accounting for metal 
complex/DNA adduct formation. Investigations on the thermal behavior of the DNA in the 
presence of the silver complex showed a stabilization of the double helix of CT DNA as its 
melting temperature increased. Consequently, the authors proposed a non-covalent reversible 
binding behavior of the complex to the DNA. By viscometry it was found that the silver 
complex induced DNA bending due to non-covalent interaction such as partial intercalation. 
Notably, complex 12 did not cause DNA cleavage as demonstrated by gel mobility studies. 
Recently, Goite and coworkers examined DNA interactions of a dinuclear silver(I) NHC 
complexes with rigid pyridine linkers (13, Figure 6).61 The anticancer activities of 13 were first 
evaluated in vitro, and the compound resulted moderately active. Upon titration of CT DNA, a 
red shift accompanied by a hypochromic effect at 237 nm (by 22%) and 280 nm (by 21%) was 
observed in the UV-vis absorption spectra, indicating a binding mode via non-covalent 
interaction. The viscosity of the DNA/13 mixture is also reduced, probably as a consequence 
of bending or twisting of the DNA.  
Similar to its corresponding silver precursor 12, the dinuclear Au(I) NHC complex 14 was 
assigned to form non-covalent π-π stacking interactions with duplex DNA as a result of the 
modified DNA melting profiles.60 Its cytotoxic activities against MCF-7, PC3, A549, HT-29 
and 4T1 cancer cell lines were in similar ranges than for the respective silver complex, but 14 
exhibited stronger interactions with DNA. Absorbance titration spectroscopy with increasing 
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amount of CT DNA showed clearer changes of the absorbance intensities than for compound 
15, namely a strong increase (81.8%) at 292 nm. The determined binding constant Kb (6.32·10
7 
M-1) was also higher for Au(I) than for the Ag(I) analogue (2.25·107 M-1). A non-covalent 
interaction or partial intercalation was further assigned to the binding mode of Au(I) complex 
14 regarding the slight decrease of the viscosity of the CT DNA/complex mixture. Interestingly, 
in contrast to the silver species, treatment of 14 affected the gel mobility of circular plasmid 
DNA (pBR322) and the authors confirmed a strong DNA interaction of the gold complex.  
Likewise, the bis-gold(I) NHC complex 15 was synthesized upon transmetalation of the silver 
bis(carbene) intermediate 13.61 However, this species did not show antiproliferative effects in 
vitro up to 30 µM, which was thought to be caused by the more hydrophilic character of the 
gold compound (logP = -1.09 vs. 0.23 for 13) most likely leading to reduced uptake. A non-
covalent binding mode was observed by the viscosity reduction of the CT/DNA mixture and by 
the titration of increasing CT DNA equivalents with 15 that showed a strong hyperchromic 
effect and a decrease in intensity of only the absorbance band at 249 nm. It is worth mentioning 
that, in contrast to 13, the gold(I) carbene (15) affected the gel mobility of plasmid DNA, as 
well as degraded the DNA. 
A series of half-sandwich ruthenium(II) containing benzyl-substituted NHC ligands with DNA 
intercalating properties showed antiproliferative activities that correlated with their 
lipophilicity,62  and in one case even exceeded the activity of cisplatin in prostate cancer cells 
(PC-3). Upon titration of the ruthenium complexes with CT DNA the resulting absorption 
spectra displayed a distinct hypochromism with a slight red shift, which suggested a stacking 
interaction between the aromatic fragments of the complexes and the DNA base pairs. 
Interestingly, apart from the chemical nuclease activity of the ruthenium(II) NHC (2), an 
additional intercalative binding mode was demonstrated.12 This complex affected the 
morphology of CT DNA as shown by CD experiments. The negative (248 nm) as well as the 
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positive (272 nm) bands of the right-handed B-DNA were clearly lowered in intensity, 
indicating destabilization of base-stacking and loss of the right-handed helicity.  
Cyclometalated ligands built from various π-conjugated organic frameworks are extensively 
exploited for their photoluminescent characteristics with respect to imaging applications.63 
Furthermore, the resulting planar and aromatic complex structures can promote intercalation of 
the metallodrug into DNA base pairs. In this context, Che and coworkers synthesized a family 
of cytotoxic gold(III) complexes bearing both NHC and cyclometalated C^N^C ligand moieties 
(e.g. 16).64 The intercalating binding mode of the complex with DNA was demonstrated by 
UV-Vis absorption titration and gel mobility studies. For example, upon addition of CT DNA 
to a solution of 16 relevant alterations of the UV-Vis spectra were observed (isosbestic points 
at 323 nm, 341 nm and 405 nm, and hyperchromicity of 36% at 380-420 nm) and the binding 
constant resulting from the intercalation was calculated as K = 5.4·105 M-1. Further studies 
highlighted the potential to induce DNA strand breaks and to prevent TopoI (topoisomerase I)-
mediated relaxation of supercoiled DNA. Based on the promising IC50 values, which were 
multiple times lower than for cisplatin, 16 was additionally evaluated in vivo. After almost a 
month of treatment with 10 mg/kg/week of 16, PLC (hepatocellular carcinoma) tumor growth 
in nude mice models was significantly suppressed (47%) with no death or loss in body weight. 
The design of metallodrugs exhibiting multiple modes of action is a promising approach in the 
development of novel anti-cancer drugs. In this context, an elegant method is the use of organic 
DNA intercalators incorporated into the ligand system of gold(I) centers which are usually 
associated with protein-targeting. For example, Ott and coworkers synthesized a series of 
gold(I) N-heterocyclic carbene compounds substituted with naphtalimides (17a-d, Figure 6), 
an aromatic system well-known as efficient DNA intercalator, potential cellular imaging agent 
and marker for cancer.65 The intercalating properties were confirmed by circular dichroism, 
while the Au(I)-conjugate retained inhibitory properties to TrxR.66 In vitro studies showed 
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antiproliferative effects against MCF-7 human breast adenocarcinoma and HT-29 colon 
carcinoma cells. Similar to the intercalating naphtalimide-based ligand, DNA stabilization was 
also observed upon treatment of CT DNA with the respective gold(I) compounds, expressed as 
an increase of the thermal denaturation temperature, ΔTm = 11 °C (17a); 6 °C (17b); 4 °C (17c); 
6 °C (17d). Furthermore, circular dichroism (CD) spectra showed that 17a behaved similar to 
the respective imidazolium salts by mainly affecting the base stacking of CT DNA. In contrast, 
17b-d additionally distorted the B conformation of DNA as suggested by the increase of the 
signal intensity at 275 nm.  
 
Fig. 6 - Intercalating metal NHC complexes. 
Building on a similar approach,59 NHC-based complexes exhibiting such a dual binding mode 
were prepared with ruthenium(II) (18) and rhodium(I) (19) ions (Figure 6).67 Regarding the 
antiproliferative effects, the rhodium-based compound exhibited low micromolar activities in 
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the breast carcinoma (MCF-7) and colon carcinoma (HT-29) cell lines, while the ruthenium 
congener (18) was virtually inactive. Comparative mechanistic studies revealed an overall 
stronger DNA interaction of the rhodium-based complex 19. UV-Vis titration absorption 
spectroscopy showed hypochromicity with a slight red shift indicating an intercalative binding 
mode. Notably, circular dichroism experiments revealed an enhanced DNA interaction of the 
metal-naphtalimide conjugates. Both complexes generated a band (~ 350 nm) when attached to 
the DNA while this effect was not observed for the free ligand. The binding constants, 
determined via UV-Vis spectroscopy and CD, displayed an overall higher DNA binding affinity 
of the rhodium-based 19. Moreover, mass spectrometric studies demonstrated that both 
complexes were able to bind covalently to the model nucleobase 9-ethylguanine. Interestingly, 
photophysical properties of both compounds, deriving from the naphtalimide moiety, are 
quenched upon metalation.   
 
2.2. Mismatch DNA 
Misincorporated nucleobases during DNA synthesis that do not match the complementary base 
pair are termed DNA mismatches.68 Cells evolved elaborate mechanisms, which sense and 
repair such defects by excision and rely on the DNA mismatch-repair machinery for this 
purpose. As a consequence, persistent point-mutations during DNA replication occur only at a 
part-per-billion frequency in healthy cells. Some colon cancers may show defects in the DNA 
mismatch-repair machinery and this feature may be valuable as a diagnostic or therapeutic 
strategy by targeting such mismatches.69 
Some small molecules, including metal-based anticancer agents were shown to interact with 
mismatched DNA bases.69,70 The first report on an intercalating ruthenium metallodrug by X-
ray diffraction revealed insertion into the site of the A:A mismatch on the oligonucleotide 5’-
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(dCGGAAATTACCG)2-3’ by expulsing both adenines, which then stacked with the ancillary 
metal-bound phenanthroline ligands (Figure 3B).71 In contrast to platinum anticancer agents 
binding to duplex DNA via the major groove, this ruthenium compound inserted in the minor 
groove. In addition to binding to the mismatched site, the metal complex was also able to bind 
non-covalently to other (abasic) sites, which suggested low selectivity for the mismatch.  
Recently, organometallic platinum(II) NHC complexes were reported to probe selectively 
mismatched DNA over matched DNA.72 Strikingly, a [Pt(C^N^N)(NHC)]+ derivative 
(HC^N^N = 6-phenyl-2,2’-bipyridine and NHC = n-butyl functionalized) (20, Figure 7), was 
found to selectively intercalate into C:C mismatches even over other mismatch types, e.g. C:T 
or A:C. However, this selectivity was partially reduced when extending the scaffold to a 
homobimetallic compound of the form [Pt2(C^N^N)2(μ-L)]2+ (L = bridging biscarbene (21) or 
diphosphine), that was expected to benefit from additional secondary stabilization of the 
backbone with the DNA. QM/MM calculations of a representative homobimetallic compound 
showed that the planar cyclometalated C^N^N ring systems inserted into the mismatch and was 
able to π-stack with the nucleobases, while the orthogonal backbone engages in secondary 
hydrophobic interactions with the expulsed nucleobases from the mismatch. Moreover, the 
homobimetallic species is 2+ charged, which is responsible for additional electrostatic 
stabilization upon binding to the DNA structure. 
Based on these observations, targeting mismatched DNA by organometallic NHC compounds 
may prove to be a viable strategy to diagnose or treat cancer types that are characterized by a 
deficiency in the mismatch repair machinery. Highly selective mismatch targeting NHC 
compounds could be designed to feature ample secondary interactions with the expulsed 
nucleotides to additionally stabilize the drug–target interaction. 
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Fig. 7 - Metal NHC complexes targeting mismatched DNA. 
 
2.3. G-quadruplexes  
G-quadruplexes (G4s) are guanosine-rich intrastrand secondary structures of DNA formed by 
three stacks of guanosine quartets and each quartet assembles in a pseudoplanar arrangement. 
The hydrogen bond system is formed by a Watson-Crick edge of one guanine with a Hoogsteen 
edge of its neighbour, and the stacks are stabilized by two potassium ions (Figure 8A).73 G4s 
play important roles in cancer progression because of their involvement in telomeric and 
promoter regions of the genome.74 Several types of G4 structures have been identified so far by 
NMR and X-ray diffraction studies, including telomeric repeat DNA consisting of d(TTAGGG) 
repeats, and promoter regions of oncogenes including MYC, KIT1, KRAS etc. (Figure 8B). 
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Fig. 8 - (A) Base-pairing of G-quadruplexes and (B) representative examples including 
telomeric G4s (pdb 5CCW) and promoter G4s for MYC (pdb 1XAV) and KIT1 (pdb 2O3M). 
 
2.3.1 Telomeric G4s 
G4s were initially characterized as guanine-rich repeats at the single-stranded ends of 
chromosomes, i.e. the 3’-end in a single strand of about 200 nucleotides. These telomeric 
repeats protect against DNA degradation by folding into stacks of tightly packed G4s.75 It was 
also found that the enzyme telomerase would catalyse the extension of these repeats after 
cellular duplication events by synthesising d(TTAGGG) telomeric repeats. Overexpression of 
telomerase is found in many cancer types and supports cellular immortality, which is one of the 
hallmarks of cancer.76 It was therefore sought to stabilize G4s in telomeres by small molecules, 
which in turn would inhibit telomerase activity and thus, show anticancer effects.75,77  
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Recently, a bis-NHC gold(I) complex - [Au(9-methylcaffein-8-ylidene)2]
+ (22, Figure 9) - 
bearing the natural product caffeine as carbene ligand, has been demonstrated by DNA FRET 
melting assays to selectively targeting telomeric G4 structures with respect to duplex DNA, 
while showing selective antiproliferative effects on tumorigenic over healthy cells.78 The G4 
consisted of a 23 nucleotide telomere repeat sequence d(TAGGG(TTAGGG)3. The X-ray 
structure indicated that the loops of the telomeric G4 do not cover the G-quartets, but extend to 
the side of the structure in a propeller configuration (Figure 8B). This feature allows telomeric 
G4s to form stacks and the planar 22 was then shown to bind non-covalently between 
neighboring telomeric G4s.79 Moreover, the 3,3´-end accommodated one and the 5,5´-end 
accommodated two [Au(9-methylcaffein-8-ylidene)2]
+ ions. This compound shows 
characteristic features for G4 stabilization including (i) a planar structure (ii) delocalized 
guanine analogues suitable for π-stacking and (iii) a central positively-charged gold(I) atom 
adding electrostatic interactions. 
Preliminary structure-activity relationships on this compound family revealed that N9-
derivatizations of the xanthine backbone affected the selectivity over duplex DNA. This is 
exemplified by the methylbenzoate derivative [Au(9-{4-methylbenzoate}caffein-8-ylidene)2]
+ 
(23, Figure 9). The bulky ligand brakes the planarity of the organometallic compound and 
results in an orthogonal arrangement of the xanthine ligands.78 This derivative was equally 
potent, but less selective for telomeric G4 over duplex DNA compared to the methyl-derivative 
and suggests that it may interact with telomeric G4 in a different manner. Compound 22 and 
analogues were evaluated for their toxicity in an ex vivo model that uses tissue slices.78 Notably, 
the xanthine-derived compounds were not toxic in healthy tissues, at variance with the 
benzimidazole-derived analogues. 
An additional example of an organometallic NHC-type stabilizer of telomeric G4s was reported 
by conjugating a trans platinum(II)-NHC moiety to pyridostatin (24, Figure 9).80 The latter is 
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a selective telomeric G4 binder and was expected to direct the platinum(II)-type moiety to 
specific locations in the nucleus, where the Pt(II) moiety could then bind form to G4s via 
irreversible coordinative bonds. The compound was shown to cause distinctly different cellular 
effects compared to cisplatin and displaced the telomere maintenance protein TRF2 from 
telomeres, but not to such an extent as to induce telomere shortening. Although conclusive 
structural information has not yet been provided for the interaction of 24 with DNA at a 
molecular level, the displacement of TRF2 provides evidence that 24 targets telomeric DNA in 
cellular systems, and represents one of the few examples of a validated target engagement in 
cells.  
 
 
Fig. 9 - NHC metal complexes targeting G-quadruplex DNA. 
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2.3.2. Promoter G4s 
In addition to telomeric G4s, it was shown using genome sequencing that approximately 
700,000 DNA G4-like sequences,81 while bioinformatic studies reported around 350,000 
sequences with the potential to form G4 structures.82 Finally, immunoprecipitating G4 
structures from cells together with high-throughput sequencing revealed approximately 10,000 
G4 structures in human chromatin.83 It was revealed that these G4 sequences were especially 
present in non-nucleosomal regions in the genome and that they would enrich in promoter 
regions of genes. Promoter G4s occur once per promoter region and although small in size, they 
show specific architectures according to the arrangement of the loops connecting the guanine 
stacks, which in principle allow for specific drug targeting, e.g. the G4 sequence in the promoter 
region of the KIT1 gene is largely conserved and unique in the human genome, and so is 
presumably its structure. KIT is a proto-oncogene encoding a receptor tyrosine kinase that 
stimulates proliferation.84 It has been proposed that formation of the quadruplex structure in 
these regions may control transcription and as a consequence, the expression of the 
corresponding oncogenes. Thus, stabilizing G4s by small molecules may be utilized to treat 
KRAS, KIT1 or c-MYC driven cancers, which are inherently difficult to treat, e.g. lung 
adenocarcinoma.85,86 Promoter G4s are intrastrand structures on duplex DNA and the 
complementary strand displays a C-rich sequence that may arrange into the so-called i-motif, 
which is one of the few known cases of systematic base intercalations.87 This complementary 
structure is less investigated than the G4 but may prove to be equally useful in a therapeutic or 
diagnostic context. 
 
3. Conclusions and Future Directions 
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The use of metal carbene complexes in various fields beyond catalysis has experienced 
substantial advances during the last years, including for biomedical applications. Recent proof-
of-principle studies on organometallic NHC anticancer agents showed that this class of 
compounds is able to target several canonical and non-canonical DNA secondary structures.  In 
detail, metal NHC complexes were shown to interact with duplex, mismatched and G-
quadruplex DNA, while examples of other classes of metal-based anticancer agents exist that 
inhibit replication forks,89 by interacting with DNA three-way junctions,90 which in the future 
may become amenable to targeting by NHC ligated organometallics. Concerning the type of 
interaction, metal NHC complexes feature different DNA binding modes, including 
coordinative and intercalating, and some of them show induction of oxidative damage; thus, 
revealing the potential of organometallic scaffolds to allow a plethora of strategies to target 
nucleic acids, for either therapy or imaging. For example, [Au(NHC)2]
+ complexes with 
appropriately functionalized wingtip groups constitute components that combine luminescent 
and antiproliferative properties in the same scaffold. Such chemical tools would be ideal to 
study the predominate questions of metallodrugs in cells with regard to metal speciation and 
validation of the pharmacological mechanisms. In fact, a combination of fluorescence 
spectroscopy and isotope-specific mass spectrometry would allow to follow not only the 
compounds distribution in cells, but also the structural integrity of the compound, e.g. with 
regard to ligand exchange reactions. This can even be extended by X-ray absorption near-edge 
spectroscopy (XANES) to study the composition of the first coordination sphere and the 
oxidation state of metallodrugs in tissues.91 Notably, advanced mass spectrometric techniques 
emerge as promising tools to generate hypotheses on target identification92 and mechanisms of 
action in the cellular context.93  
Furthermore, recent developments in the DNA targeted field of organometallic NHC anticancer 
agents show also a trend towards molecular and systems biology approaches in order to 
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elucidate mechanisms of action or effective signal transduction pathways and in situ chemical 
affinity capture will presumably increase in popularity to validate binding of selected 
compounds to specific DNA secondary structures in vitro.86 Similarly, ELISA microarrays may 
prove useful to globally elucidate signalling events upon drug administration.94  
It is evident that future research in the discovery and development of organometallic NHC 
compounds has to be directed towards a more rational drug discovery of therapeutic compounds 
with respect to the targeting of specific DNA secondary structures. Such molecules may be 
developed also as chemical probes to aid in uncovering the functions of these structures in 
cancer biology in more detail.  
Although the spatial arrangement of the nucleotides in DNA secondary structures may be 
unique, it remains to be proven whether specific DNA secondary structures can be targeted at 
all given the complexity of genomic DNA. In particular, targeting of G4s of specific genes 
would enable a powerful approach for gene silencing at the level of transcription initiation and 
would be equivalent to a small molecule gene knock-down. Of note, although telomeric and 
promoter G4s show marked structural differences, it remains challenging to develop selective 
agents for either type, although coordination metal-based compounds have shown already 
interesting properties.95 Similarly, current research efforts are directed towards small molecules 
that target specific promoter G4s. Moreover, despite intensive research in this area, the actual 
function of G4s in vivo has not yet been fully understood. Therefore, significant efforts have 
been devoted to the discovery of specific probes for visualizing and distinguishing G4 structures 
from other nucleic acid molecules likely to be found in biological environments.96 In this 
context, based on the representative examples described in this review, metal NHCs certainly 
hold great promise. 
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